Bavarian Nordic (OTCMKTS:BVNRY) Sees Large Volume Increase – Should You Buy?

Bavarian Nordic (OTCMKTS:BVNRY) shares saw unusually-high trading volume on Wednesday . Approximately 7,557 shares were traded during mid-day trading, an increase of 117% from the previous session’s volume of 3,489 shares.The stock last traded at $9.52 and had previously closed at $9.6050.

Bavarian Nordic Price Performance

The firm has a market cap of $2.24 billion, a price-to-earnings ratio of 12.38 and a beta of 1.20. The company’s fifty day moving average is $9.58 and its 200 day moving average is $9.87.

Bavarian Nordic (OTCMKTS:BVNRY) last issued its quarterly earnings results on Wednesday, May 13th. The company reported $0.01 earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 19.74% and a return on equity of 9.32%. The firm had revenue of $165.70 million for the quarter.

About Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company specializing in the development, manufacture and commercialization of vaccines and immunotherapies. Founded in 1994 and headquartered in Martinsried, Germany, the company combines internal research capabilities with in-house manufacturing to address serious infectious diseases and cancer indications. Bavarian Nordic’s operations encompass preclinical research, clinical development and commercial supply, with a strategic focus on leveraging its proprietary viral vector platforms.

The company’s commercial portfolio includes approved prophylactic vaccines such as Jynneos™ (marketed as Imvamune®/Imvanex®) for the prevention of smallpox and monkeypox in the United States, European Union and Canada; Rabipur® for rabies prevention; and Encepur® against tick-borne encephalitis.